Medicenna Therapeutics Corp. (MDNAF) 股价，以美元计价

Medicenna is a clinical stage immuno-oncology company developing novel highly selective versions of Superkines and first in class Empowered Cytokines (ECs). Medicenna is specifically targeting the Interleukin-4 Receptor (IL4R), which is over-expressed by at least 20 different types of cancer affecting more than one million new cancer patients every year. A Phase 2b clinical trial for recurrent glioblastoma (rGBM) is enrolling patients at leading brain cancer centres in the US using Medicenna's lead IL4-EC, MDNA55. MDNA55 has completed 3 clinical trials in 72 patients, including 66 adults with rGBM, demonstrated compelling efficacy and obtained Fast-Track and Orphan Drug status from USFDA. Unlike most other cancer therapies, Medicenna's IL4-ECs have the potential to purge both the tumor and the immunosuppressive tumor microenvironment, offering a unique treatment paradigm for a large majority of cancer patients.